NICE scopes Sanofi/Regeneron's Zaltrap for colorectal cancer
This article was originally published in Scrip
Executive Summary
Sanofi/Regenron's Zaltrap (aflibercept) will shortly be up for review by NICE, the health technology appraisal institute for England and Wales, as a treatment for metastatic colorectal cancer that has progressed after oxaliplatin-based chemotherapy. The institute has put out for consultation its draft scope.
You may also be interested in...
New Filings At The EMA
New medicines under evaluation at the European Medicines Agency.
UK: Commercial Framework Sheds Light On Working With NHS And NICE
The final text brings some changes, including the introduction of an escalation process when companies and NHS England cannot agree.
Time Is Ripe For Global Action On Orphan Biosimilars
European industry association wants global convergence on development requirements, though the European Medicines Agency says that this would prove challenging.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: